List of Excipients in Branded Drug FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI

« Back to Dashboard

Generic Drugs Containing FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI

Company	Ingredient	NDC	Excipient
Walgreens Company	fexofenadine hcl and pseudoephedrine hci	0363-1606	CROSCARMELLOSE SODIUM
Walgreens Company	fexofenadine hcl and pseudoephedrine hci	0363-1606	FERRIC OXIDE RED
Walgreens Company	fexofenadine hcl and pseudoephedrine hci	0363-1606	HYPROMELLOSES

What are the Most Frequently-Used Excipients in FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI?

# Of NDCs	Excipient
2	ACETYLTRIBUTYL CITRATE
2	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Fexofenadine HCl and Pseudoephedrine HCl Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Fexofenadine HCl and pseudoephedrine HCl combination products are mature oral extended-release medicines sold primarily as 12-hour and 24-hour tablets. The commercial opportunity is not based on new chemical-entity exclusivity. It is based on reliable release control, tablet robustness, lower manufacturing cost, differentiated packaging, age-appropriate dosing, and regulatory execution.

The central formulation challenge is combining a rapidly dissolving antihistamine with a decongestant that requires controlled release. Excipient selection must protect fexofenadine dissolution, control pseudoephedrine release, prevent dose dumping, and preserve tablet integrity during packaging and distribution.

What is the regulatory status of fexofenadine HCl and pseudoephedrine HCl?

Fexofenadine HCl is a second-generation H1 antihistamine. Pseudoephedrine HCl is an oral sympathomimetic decongestant. The combination is approved in the United States as an extended-release tablet under the Allegra-D brand and through generic abbreviated new drug applications.

The principal dose presentations are:

Product type	Fexofenadine HCl	Pseudoephedrine HCl	Release profile
12-hour tablet	60 mg	120 mg	Extended release
24-hour tablet	180 mg	240 mg	Extended release

The reference products are marketed by Sanofi Consumer Healthcare or related commercial entities under the Allegra-D brand. FDA labeling directs patients to swallow the tablets whole and not crush or chew them, reflecting the importance of the extended-release design (U.S. Food and Drug Administration [FDA], 2023a; DailyMed, 2023a).

Fexofenadine is also sold as a standalone immediate-release product. Pseudoephedrine is sold in immediate-release and extended-release products, including combination products with other antihistamines.

What excipients are used in fexofenadine-pseudoephedrine extended-release tablets?

Reference-label inactive ingredients include conventional tablet diluents, binders, disintegrants, lubricants, and release-controlling polymers. Exact excipient compositions vary by strength, manufacturer, and product version.

Common excipient categories include:

Excipient function	Representative materials	Formulation purpose
Diluent and compressibility aid	Microcrystalline cellulose	Supports tablet mass, hardness, and content uniformity
Binder	Povidone, hydroxypropyl cellulose	Improves granule and tablet cohesion
Release-control polymer	Hypromellose	Controls pseudoephedrine diffusion and matrix erosion
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Promotes breakup of immediate-release portions
Lubricant	Magnesium stearate	Reduces die-wall friction and ejection force
Film former	Hypromellose and related coating polymers	Protects the tablet and controls appearance
Glidant or processing aid	Colloidal silicon dioxide, where used	Improves powder flow
Opacifier or colorant	Titanium dioxide, iron oxides, approved colorants	Product identification and light protection

The formulation should not treat fexofenadine and pseudoephedrine as interchangeable release targets. Fexofenadine generally requires rapid availability, while pseudoephedrine is the component for which prolonged release is commercially and therapeutically important.

Which excipients are most important for release control?

Hypromellose is the leading development candidate for a hydrophilic matrix. Its viscosity grade, substitution level, particle size, and concentration affect water penetration, gel strength, erosion, and pseudoephedrine diffusion.

A practical development platform can use:

1. An immediate-release fexofenadine phase.
2. A hydrophilic pseudoephedrine matrix.
3. A film coating that protects the tablet without materially altering dissolution.

A monolithic matrix tablet may reduce manufacturing complexity, but a bilayer tablet can provide stronger control over the two active ingredients. Bilayer architecture permits rapid fexofenadine release from one layer and prolonged pseudoephedrine delivery from the other. It also creates additional process risks, including layer adhesion, weight variation, cross-contamination, and delamination.

How should an excipient strategy address fexofenadine compatibility?

Fexofenadine HCl has high aqueous solubility relative to many oral drug substances. Its formulation risk is therefore less about achieving dissolution and more about controlling dose uniformity, powder flow, polymorphic or solid-state behavior, and interaction with excipients.

Key compatibility screens should evaluate:

• Moisture uptake and water activity.
• Chemical stability in the presence of reducing sugars and reactive impurities.
• Drug-polymer interaction.
• Lubricant concentration and mixing time.
• Dissolution after accelerated storage.
• Assay and content uniformity across the tablet.
• Extractables and leachables from high-barrier packaging.

A direct-compression formulation is commercially attractive if the active pharmaceutical ingredients have adequate flow and compressibility. Granulation may be preferable when the formula has poor flow, high segregation risk, or inadequate mechanical strength.

Pseudoephedrine HCl is relatively water soluble and can produce rapid release if it is insufficiently embedded in the polymer matrix. Increasing polymer loading can prolong release, but excessive polymer can create large tablets, slower onset, higher manufacturing cost, and undesirable dissolution tails.

What formulations are protected by excipient and delivery-system patents?

The active ingredients and basic combination concept are mature. Commercial protection, where available, is more likely to arise from:

• Specific extended-release matrices.
• Bilayer or multilayer tablet architecture.
• Coating systems.
• Abuse-deterrent or tamper-resistant delivery.
• Manufacturing processes.
• Particle-size distributions.
• Drug-polymer ratios.
• Dissolution profiles.
• Packaging configurations.
• Stability improvements.

A formulation patent must be assessed claim by claim. The presence of a particular excipient in a commercial label does not establish patent protection. Conversely, a patent may claim a polymer combination, process parameter, or dissolution range without naming every commercial excipient.

For a generic developer, the principal intellectual-property task is an Orange Book review of the reference NDA and a separate search of issued U.S. and foreign patents covering extended-release combinations.

What is the Orange Book status of fexofenadine-pseudoephedrine products?

The FDA Orange Book identifies approved reference listed drugs, patent information submitted for listed products, and regulatory exclusivity. The reference combination products are old enough that the core composition and basic extended-release concepts are generally exposed to generic competition.

Orange Book analysis should distinguish:

Issue	Commercial implication
Listed patent	May require a Paragraph IV certification or a patent-expiration certification
Unlisted formulation concept	May still create litigation risk if separately patented
Method-of-use patent	May affect labeling or a section viii carve-out
Regulatory exclusivity	Can delay approval even when patent barriers are absent
NDA reference status	Determines the ANDA reference product and bioequivalence pathway

The Orange Book is not a complete patent landscape. It does not generally capture every process, manufacturing, foreign, trade-secret, or non-listed formulation right. FDA approval and patent clearance are separate workstreams (FDA, 2024a).

When does fexofenadine-pseudoephedrine lose exclusivity?

The core products have already entered the post-exclusivity generic market. The meaningful commercial question is not when the molecule loses exclusivity, but whether a new formulation obtains independent protection.

Potential remaining barriers can include:

• Later-issued formulation patents.
• Pediatric exclusivity attached to a specific regulatory product.
• Patent litigation triggered by an ANDA Paragraph IV filing.
• Product-specific manufacturing claims.
• State and federal controls on pseudoephedrine distribution.

There is no biosimilar pathway for this product. Fexofenadine HCl and pseudoephedrine HCl are chemically synthesized small molecules and are regulated through the generic-drug framework, not the biosimilar pathway under the Public Health Service Act.

What Paragraph IV challenges and litigation risks exist?

A generic applicant seeking approval before expiration of a listed patent may submit a Paragraph IV certification stating that the patent is invalid, unenforceable, or not infringed. The patent holder can file suit within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework (FDA, 2024b).

For this combination, litigation risk is more likely to center on formulation and release claims than on the basic active ingredients. A due-diligence review should examine:

• ANDA approval dates.
• Paragraph IV notices.
• District-court complaints.
• Patent numbers asserted in litigation.
• Claim construction rulings.
• Settlements permitting an authorized or licensed generic.
• Whether the settlement contains supply, license, or launch restrictions.

No conclusion about current litigation exposure should be drawn from the absence of a lawsuit in a commercial database. Litigation records must be checked against PACER, FDA records, the Orange Book, and patent databases.

How strong is the patent estate for this combination?

The patent estate is likely weaker than the estate for a recently approved specialty drug because:

• Both active ingredients are long-established.
• Immediate-release and extended-release pseudoephedrine products are mature.
• The Allegra-D commercial concept has been public for decades.
• Multiple generic manufacturers have experience with the dosage form.

The strongest residual protection would usually be a narrow formulation patent with a measurable dissolution limitation, a manufacturing claim difficult to design around, or a product-specific combination of polymers and process conditions.

A broad claim covering fexofenadine, pseudoephedrine, and an extended-release tablet would face greater validity and prior-art pressure than a narrow claim tied to a defined release profile or manufacturing sequence.

Which excipient platforms create commercial opportunities?

Low-cost generic substitution

The largest opportunity is a cost-efficient 12-hour or 24-hour tablet using a conventional hydrophilic matrix. The target profile is:

• High tablet yield.
• Direct compression or a short wet-granulation process.
• Low polymer loading consistent with release control.
• Robust content uniformity.
• Stable dissolution through shelf life.
• Minimal coating complexity.

The primary competitive advantage is manufacturing reliability rather than novel pharmacology.

Private-label and retailer products

Retailers and pharmacy chains can support store-brand versions if the product meets FDA ANDA requirements and can be supplied consistently. The commercial model benefits from:

• Standardized excipient sourcing.
• Multiple approved packaging configurations.
• Dual-source manufacturing.
• National Drug Code portfolio management.
• Strong controls over pseudoephedrine inventory.

24-hour convenience products

The 24-hour strength offers a convenience advantage over 12-hour dosing. The formulation opportunity is to maintain a predictable release curve without increasing tablet size excessively. A high-viscosity polymer matrix can reduce dosing frequency, but development must control the risk of incomplete release or excessive late-stage retention.

Pediatric and age-appropriate formats

Pediatric opportunity is limited by pseudoephedrine safety considerations, dosing complexity, and the difficulty of making a tamper-resistant extended-release product in a liquid or chewable format. A liquid product can create rapid pseudoephedrine delivery and may not replicate the reference release profile. Orally disintegrating tablets are also challenging because extended-release granules may be chewed or damaged.

A more realistic opportunity is differentiated packaging and dosing aids for adolescents and adults, subject to approved labeling.

Tamper-resistant and controlled-access packaging

Pseudoephedrine is subject to federal retail-sale restrictions and purchase-quantity controls under the Combat Methamphetamine Epidemic Act. Packaging cannot eliminate these obligations, but it can reduce diversion and improve inventory control. Commercial options include:

• Unit-dose blister packaging.
• Limited-count cartons.
• Serialized or traceable packaging.
• Behind-the-counter distribution.
• Clear purchase instructions.
• Moisture-barrier blister systems.

Packaging is a regulatory and supply-chain differentiator rather than a substitute for drug-product innovation (U.S. Drug Enforcement Administration, 2024).

How does fexofenadine-pseudoephedrine compare with competing allergy products?

Product category	Antihistamine	Decongestant	Main commercial advantage	Main limitation
Fexofenadine plus pseudoephedrine	Fexofenadine	Oral pseudoephedrine	Non-sedating antihistamine with systemic decongestion	Pseudoephedrine controls and cardiovascular warnings
Cetirizine plus pseudoephedrine	Cetirizine	Oral pseudoephedrine	Broad generic availability	Greater sedation potential for some patients
Loratadine plus pseudoephedrine	Loratadine	Oral pseudoephedrine	Established once-daily formats	Competitive pressure and mature pricing
Fexofenadine alone	Fexofenadine	None	Low sedation profile	Does not relieve nasal congestion as strongly
Intranasal steroid	Various	Local anti-inflammatory effect	Strong congestion control without oral stimulant	Requires regular use and correct technique

The combination competes against both other oral antihistamine-decongestant products and intranasal therapies. Formulation development should therefore prioritize onset, duration, tablet size, tolerability, and retail availability.

What manufacturing and intellectual-property barriers matter most?

The major manufacturing barriers are process control and supply-chain compliance.

Manufacturing risks

• Segregation caused by differences in particle size and density.
• Inconsistent pseudoephedrine release from matrix tablets.
• Overlubrication and slower dissolution.
• Layer weight variation in bilayer tablets.
• Tablet capping or lamination.
• Moisture-related stability changes.
• Inadequate coating adhesion.
• Pseudoephedrine inventory and diversion controls.
• Reliance on a single polymer or API supplier.

Intellectual-property risks

• Extended-release formulation claims.
• Dissolution-profile claims.
• Bilayer tablet claims.
• Polymer-combination claims.
• Process patents.
• Packaging or tamper-resistance claims.
• Method-of-use claims for allergic rhinitis or nasal congestion.

A freedom-to-operate program should cover the United States, Canada, Europe, Australia, Japan, and major emerging markets. Patent duration and enforceability differ materially by jurisdiction. A product cleared for U.S. launch may still face active formulation patents elsewhere.

What licensing deals are relevant?

Licensing opportunities are more likely to involve manufacturing, distribution, private-label supply, or authorized-generic arrangements than molecule licensing.

Potential transaction structures include:

• Contract development and manufacturing of an ANDA product.
• Authorized-generic supply from an NDA holder.
• Regional commercialization rights.
• Retailer private-label supply agreements.
• Technology licenses for controlled-release matrices.
• Packaging and serialization partnerships.
• Dual-source API and finished-dose supply agreements.

The economic value of a license depends on remaining patent life, ANDA status, supply obligations, permitted launch date, channel access, and pseudoephedrine compliance costs. A formulation license without regulatory approval or demonstrated bioequivalence has limited immediate value.

What revenue exposure and generic launch scenarios should investors consider?

Public companies generally do not disclose standalone revenue for this combination. Revenue exposure should therefore be estimated from product-level sales data, prescription and OTC channel data, shipment volumes, and retailer presence rather than inferred from corporate segment revenue.

Three launch scenarios are commercially relevant:

Scenario	Market effect	Formulation requirement
Single low-cost generic	Moderate price erosion	Conventional bioequivalent tablet
Several generic suppliers	Greater price erosion and retailer switching	Reliable scale and low cost
Authorized generic plus independent ANDAs	Rapid channel fragmentation	High-volume supply and strong compliance
Differentiated reformulation	Smaller premium segment	Demonstrated convenience, stability, or packaging benefit

The 24-hour product may support stronger brand recognition, but generic substitution and retailer purchasing power limit premium pricing. A new excipient system must produce a measurable advantage to justify development expense.

What is the recommended excipient development strategy?

A commercially disciplined program should use a staged approach:

1. Establish a reference dissolution target for both strengths.
2. Screen hypromellose grades and polymer concentrations.
3. Compare direct compression, granulation, and bilayer manufacture.
4. Confirm fexofenadine release before pseudoephedrine matrix erosion accelerates.
5. Test dissolution under pH and agitation conditions relevant to regulatory expectations.
6. Conduct drug-excipient compatibility and accelerated stability studies.
7. Build a design space around polymer viscosity, lubricant level, compression force, and coating weight.
8. Select high-barrier packaging early.
9. Confirm bioequivalence strategy before committing to a complex dosage form.
10. Perform Orange Book and global freedom-to-operate analysis before scale-up.

The preferred first platform is usually a conventional matrix tablet with established excipients. Bilayer or proprietary polymer systems should be pursued only when they solve a defined commercial problem, such as tablet-size reduction, improved release consistency, or a differentiated regulatory pathway.

Key Takeaways

• Fexofenadine HCl and pseudoephedrine HCl are mature small-molecule actives with generic competition.
• The principal formulation opportunity is controlled pseudoephedrine release with rapid and reliable fexofenadine availability.
• Hypromellose-based matrices, microcrystalline cellulose, povidone, conventional disintegrants, and magnesium stearate provide a practical excipient platform.
• The strongest residual IP opportunities are likely to involve release profiles, polymer combinations, manufacturing processes, and packaging rather than the active ingredients.
• Biosimilar risk does not apply; Hatch-Waxman ANDA and Paragraph IV analysis does.
• Pseudoephedrine sales controls create supply-chain and channel-management obligations that affect commercial value.
• The most credible commercial opportunities are low-cost generic supply, private-label products, 24-hour formulations, and compliance-focused packaging.
• A new excipient strategy requires a measurable advantage over conventional generic matrix technology.

FAQs

Can fexofenadine and pseudoephedrine be formulated in a liquid product?

Yes, but an oral liquid would not automatically reproduce the extended-release profile of the reference tablet. A liquid product would require a separate regulatory and pharmacokinetic strategy.

Which polymer is most suitable for pseudoephedrine extended release?

Hypromellose is a practical first-line candidate because it is widely used, scalable, and available in multiple viscosity grades. The optimal grade and concentration depend on tablet geometry, dose, compression, and target dissolution.

Does a new excipient create patent protection by itself?

No. Patentability generally depends on the claimed formulation, release behavior, process, or unexpected technical effect. Merely substituting one conventional excipient for another may not provide meaningful protection.

Are fexofenadine-pseudoephedrine tablets subject to pseudoephedrine purchase limits?

Yes. Federal and state controls may apply because pseudoephedrine is a regulated precursor. Requirements can include behind-the-counter sale, identification checks, transaction recording, and purchase limits.

Is a bilayer tablet commercially superior to a monolithic matrix tablet?

Not automatically. A bilayer tablet can improve separation of release functions, but it increases equipment, validation, weight-control, and delamination risks. A monolithic matrix is usually the lower-complexity starting platform.

References

DailyMed. (2023a). Allegra-D 24 hour extended-release tablets: Prescribing information. U.S. National Library of Medicine.

U.S. Drug Enforcement Administration. (2024). Retail sales of scheduled listed chemical products containing ephedrine and pseudoephedrine. U.S. Department of Justice.

U.S. Food and Drug Administration. (2023a). Allegra-D 12 hour and Allegra-D 24 hour labeling. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2024b). Hatch-Waxman and abbreviated new drug application patent certifications. U.S. Department of Health and Human Services.